SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.140-0.3%2:47 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BoredMember who wrote (10195)5/8/2018 4:53:20 PM
From: HardToFind1 Recommendation

Recommended By
drkaz

  Read Replies (1) of 12873
 
If Nanoviricides is the primary source of revenue for Theracour as you profess, then surely Nanoviricides is extremely important to Theracour and Dr. Anil Diwan. Isn't that abundantly clear?
Yes, important as a source of money. And to some degree as an owner of NNVC shares. But, any massive dilution to NNVC shareholders doesn't impact Diwan in the same painful way. Diwan would then have money to finance his research, but the current shareholders would have lost a large portion of their equity interest.

So yes, NNVC is extremely important to TheraCour and Dr. Anil Diwan. But that is not the same as the fate of the shareholders being extremely important to TheraCour and Dr. Diwan.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News